Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanreotide Autogel for treatment-resistant gastroesophageal reflux with persistent endoscopic esophagitis
2013-004232-29Phase 2Completed
- Sponsor
- UZ Brussel
- Start
- Dec 2013
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lanreotide in gastroesophageal reflux disease (GERD) and erosive esophagitis (EE), sponsored by UZ Brussel. Started Dec 2013; status: completed.
02
Drugs
lanreotide
03
Conditions
gastroesophageal reflux disease (GERD)erosive esophagitis (EE)
Beyond the preview
Go deeper on 2013-004232-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004232-29.